SCHEMBL1308628

SCHEMBL1308628

C=C(C)C(=O)Nc1ccc(Cl)cc1C(N)=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.62
ALDH1A1 P00352 2/20 0.62
GLA P06280 1/20 0.62
GAA P10253 1/20 0.62
HSD17B10 Q99714 1/20 0.53
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
BTK Q06187 2/20 0.43
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SERPINE1 P05121 3/20 0.41
GABRP O00591 2/20 0.40
GABRD O14764 2/20 0.40
GABRA1 P14867 2/20 0.40
GABRB1 P18505 2/20 0.40
GABRG2 P18507 2/20 0.40
GABRB3 P28472 2/20 0.40
GABRA5 P31644 2/20 0.40
GABRA3 P34903 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3044265 0.86 KDM4E (0.71) KDM4EALDH1A1GAAHSD17B10SERPINE1
SCHEMBL11536873 0.83 KDM4E (0.63) KDM4EALDH1A1GLAGAAHSD17B10
SCHEMBL1309023 0.82 ALDH1A1 (0.50) KDM4EALDH1A1GLAGAAMEN1
SCHEMBL28534851 0.81 USP2 (0.55) KDM4EALDH1A1GAAHPGDRAB9A
SCHEMBL30661117 0.80 MAPT (0.64) ALDH1A1GAASMN1; SMN2SERPINE1MAPT
SCHEMBL19253255 0.80 MAPT (0.64) ALDH1A1GAASMN1; SMN2SERPINE1MAPT
SCHEMBL19268087 0.79 TP53 (0.54) KDM4EALDH1A1HSD17B10KMT2ASMN1; SMN2
SCHEMBL19268075 0.79 GABRP (0.63) KDM4EALDH1A1HSD17B10RAB9ASMN1; SMN2
SCHEMBL8766311 0.78 MEN1 (0.59) ALDH1A1GAAMEN1KMT2ARAB9A
SCHEMBL11445926 0.77 ALDH1A1 (0.56) KDM4EALDH1A1GLAGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8053441-B2 Pyrazolylquinazolinones as potassium channel openers JANSSEN PHARMACEUTICA N.V. (BE) 2011-11-08 US disclosed
US-8053441-B2 Pyrazolylquinazolinones as potassium channel openers JANSSEN PHARMACEUTICA N.V. (BE) 2011-11-08 US disclosed
US-8053441-B2 Pyrazolylquinazolinones as potassium channel openers JANSSEN PHARMACEUTICA N.V. (BE) 2011-11-08 US disclosed
CN-101400672-A Pyrazolylquinazolinones as potassium channel openers JANSSEN PHARMACEUTICA NV (BE) 2009-04-01 CN disclosed
EP-1989197-A1 PYRAZOLYLQUINAZOLINONES AS POTASSIUM CHANNEL OPENERS Janssen Pharmaceutica, N.V. (BE) 2008-11-12 EP disclosed
WO-2007098386-A1 PYRAZOLYLQUINAZOLINONES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-30 WO disclosed
WO-2007098386-A1 PYRAZOLYLQUINAZOLINONES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-30 WO disclosed
US-20070197566-A1 NOVEL PYRAZOLYLQUINAZOLINONES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-23 US disclosed
US-20070197566-A1 NOVEL PYRAZOLYLQUINAZOLINONES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-23 US disclosed
US-20070197566-A1 NOVEL PYRAZOLYLQUINAZOLINONES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197566-A1 NOVEL PYRAZOLYLQUINAZOLINONES AS POTASSIUM CHANNEL OPENERS KCNJ2, KCNQ1, KCNN3 KDM4E 1752/4885ALDH1A1 1760/4885GLA 4488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.